Marina K Baine1, Christopher A Febres-Aldana1, Jason C Chang1, Achim A Jungbluth1, Shenon Sethi1, Cristina R Antonescu1, William D Travis1, Min-Shu Hsieh2, Mee Sook Roh3, Robert J Homer4, Marc Ladanyi1, Jacklynn V Egger5, W Victoria Lai5, Charles M Rudin5, Natasha Rekhtman6. 1. Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Department of Pathology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. 3. Department of Pathology, Dong-A University College of Medicine, Busan, Republic of Korea. 4. Department of Pathology, Yale School of Medicine, New Haven, Connecticut. 5. Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 6. Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: rekhtman@mskcc.org.
Abstract
INTRODUCTION: POU2F3 is a recent marker of a small cell lung carcinoma (SCLC) subtype related to chemosensory tuft cells (SCLC-P). The characteristics of SCLC-P have not been fully defined, and the data on POU2F3 expression in other lung tumors are scarce. METHODS: We screened 254 SCLC for POU2F3 expression and comprehensively analyzed histopathologic, genomic, and clinical characteristics of POU2F3-positive tumors. We also explored POU2F3 expression in other major lung cancer types (n = 433) and a targeted set of potential diagnostic mimics of SCLC (n = 123). RESULTS: POU2F3 was expressed in 30 of 254 (12%) SCLC and was strongly associated with low expression of standard neuroendocrine markers (synaptophysin, chromogranin A, CD56, INSM1). Notably, POU2F3 was expressed in 75% of SCLC with entirely negative or minimal neuroendocrine marker expression (15/20) and was helpful in supporting the diagnosis of SCLC in such cases. Broad targeted next-generation sequencing revealed that SCLC-P (n = 12) exhibited enrichment in several alterations, including PTEN inactivation, MYC amplifications, and 20q13 amplifications, but similar rates of RB1 and TP53 alterations as other SCLC (n = 155). Beyond SCLC, POU2F3 expression was exclusively limited to large cell neuroendocrine carcinoma (12%) and basaloid squamous cell carcinoma (22%). CONCLUSIONS: This is the largest cohort of SCLC-P clinical samples to date, where we describe the diagnostic utility of POU2F3 in a challenging subset of SCLC with low or absent expression of standard neuroendocrine markers. The distinct genomic alterations in SCLC-P may offer a novel avenue for therapeutic targeting. The role of POU2F3 in a narrow subset of other lung cancer types warrants further study.
INTRODUCTION: POU2F3 is a recent marker of a small cell lung carcinoma (SCLC) subtype related to chemosensory tuft cells (SCLC-P). The characteristics of SCLC-P have not been fully defined, and the data on POU2F3 expression in other lung tumors are scarce. METHODS: We screened 254 SCLC for POU2F3 expression and comprehensively analyzed histopathologic, genomic, and clinical characteristics of POU2F3-positive tumors. We also explored POU2F3 expression in other major lung cancer types (n = 433) and a targeted set of potential diagnostic mimics of SCLC (n = 123). RESULTS: POU2F3 was expressed in 30 of 254 (12%) SCLC and was strongly associated with low expression of standard neuroendocrine markers (synaptophysin, chromogranin A, CD56, INSM1). Notably, POU2F3 was expressed in 75% of SCLC with entirely negative or minimal neuroendocrine marker expression (15/20) and was helpful in supporting the diagnosis of SCLC in such cases. Broad targeted next-generation sequencing revealed that SCLC-P (n = 12) exhibited enrichment in several alterations, including PTEN inactivation, MYC amplifications, and 20q13 amplifications, but similar rates of RB1 and TP53 alterations as other SCLC (n = 155). Beyond SCLC, POU2F3 expression was exclusively limited to large cell neuroendocrine carcinoma (12%) and basaloid squamous cell carcinoma (22%). CONCLUSIONS: This is the largest cohort of SCLC-P clinical samples to date, where we describe the diagnostic utility of POU2F3 in a challenging subset of SCLC with low or absent expression of standard neuroendocrine markers. The distinct genomic alterations in SCLC-P may offer a novel avenue for therapeutic targeting. The role of POU2F3 in a narrow subset of other lung cancer types warrants further study.
Authors: Gurkan Mollaoglu; Matthew R Guthrie; Stefanie Böhm; Johannes Brägelmann; Ismail Can; Paul M Ballieu; Annika Marx; Julie George; Christine Heinen; Milind D Chalishazar; Haixia Cheng; Abbie S Ireland; Kendall E Denning; Anandaroop Mukhopadhyay; Jeffery M Vahrenkamp; Kristofer C Berrett; Timothy L Mosbruger; Jun Wang; Jessica L Kohan; Mohamed E Salama; Benjamin L Witt; Martin Peifer; Roman K Thomas; Jason Gertz; Jane E Johnson; Adi F Gazdar; Robert J Wechsler-Reya; Martin L Sos; Trudy G Oliver Journal: Cancer Cell Date: 2017-01-12 Impact factor: 31.743
Authors: Klaus J Busam; Achim A Jungbluth; Natasha Rekthman; Daniel Coit; Melissa Pulitzer; Jason Bini; Reety Arora; Nicole C Hanson; Jodie A Tassello; Denise Frosina; Patrick Moore; Yuan Chang Journal: Am J Surg Pathol Date: 2009-09 Impact factor: 6.394
Authors: Robert J Cardnell; Lerong Li; Triparna Sen; Rasha Bara; Pan Tong; Junya Fujimoto; Abbie S Ireland; Matthew R Guthrie; Sheila Bheddah; Upasana Banerjee; Nene N Kalu; You-Hong Fan; Scott J Dylla; Faye M Johnson; Ignacio I Wistuba; Trudy G Oliver; John V Heymach; Bonnie S Glisson; Jing Wang; Lauren A Byers Journal: Oncotarget Date: 2017-09-01
Authors: Beáta Szeitz; Zsolt Megyesfalvi; Nicole Woldmar; Zsuzsanna Valkó; Anna Schwendenwein; Nándor Bárány; Sándor Paku; Viktória László; Helga Kiss; Edina Bugyik; Christian Lang; Attila Marcell Szász; Luciana Pizzatti; Krisztina Bogos; Mir Alireza Hoda; Konrad Hoetzenecker; György Marko-Varga; Peter Horvatovich; Balázs Döme; Karin Schelch; Melinda Rezeli Journal: Clin Transl Med Date: 2022-09